Last updated on August 2018

Dry Eye Study

Brief description of study

The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease. The product will be studied over 14 days, with 1-2 drops instilled in each eye four times daily (QID).

Clinical Study Identifier: TX211431

Find a site near you

Start Over

Oculus Research, Inc.

4170 Fayetteville Rd Raleigh, NC United States
  Connect »